183 related articles for article (PubMed ID: 22721797)
21. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
22. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
23. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
24. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
26. [Current treatment of locally advanced and metastatic prostate cancer].
Ponholzer A; Steinbacher F; Madersbacher S; Schramek P
Wien Med Wochenschr; 2011 Aug; 161(15-16):377-81. PubMed ID: 21953428
[TBL] [Abstract][Full Text] [Related]
27. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
28. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
29. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
30. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
31. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
32. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study.
Lycken M; Drevin L; Garmo H; Larsson A; Andrén O; Holmberg L; Bill-Axelson A
Scand J Urol; 2020 Jun; 54(3):208-214. PubMed ID: 32338176
[No Abstract] [Full Text] [Related]
33. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
34. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
35. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
37. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance of
Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
[TBL] [Abstract][Full Text] [Related]
39. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Armstrong AJ; Halabi S; Healy P; Lee WR; Koontz BF; Moul JW; Mundy K; Creel P; Wood S; Davis K; Carducci MA; Stein M; Hobbs C; Reimer B; Nguyen M; Anand M; Bratt L; Kim S; Tran PT; George DJ;
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):100-6. PubMed ID: 26754260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
